Japan’s drug pricing panel held its final round of industry hearings on December 10 as it heads toward the FY2026…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Diabetes Treatments: Their Development and Market
February 20, 2012
-
BUSINESS 6 SGLT-2 Inhibitors in Final Development Stage, Applications Expected in 2013
February 17, 2012
-
BUSINESS Sanofi-aventis Nichi-Iko Obtains Approval for Allegra Generic Ahead of Competitors
February 16, 2012
-
REGULATORY Over 30 Companies Target Nu-lotan Generic Listing in June, 60% Pricing Rule to Apply
February 15, 2012
-
BUSINESS Dispensing Pharmacies Set to Reopen in Disaster-Hit Areas
February 14, 2012
-
REGULATORY Healthcare Providers, Bill Payers in Face-Off Over Additional Premiums for Generic Name Prescriptions
February 13, 2012
-
BUSINESS Nichi-Iko to Shift Back Priority to Its Own Generics from Transferred Long-Listed Products
February 13, 2012
-
ORGANIZATION NPhA Compiles Draft Proposal for Mutual Understanding to Improve Distribution
February 10, 2012
-
BUSINESS Teijin Aims for ¥400 Billion in Sales in Healthcare by FY2020
February 9, 2012
-
BUSINESS Novartis President Mitani Says Diovan Patent Expiry an “Urgent Issue”
February 8, 2012
-
BUSINESS JCR to Push Joint Development with GSK, Including New Biopharmaceuticals
February 7, 2012
-
BUSINESS US, European Pharmaceutical Companies Supported by Steady Japan Business Growth
February 6, 2012
-
BUSINESS Number of MRs Breaks 60,000; Could Become Major Topic in Light of Strained Healthcare Finances
February 6, 2012
-
BUSINESS Eisai Says Impact from Generic Versions of Aricept Insignificant
February 3, 2012
-
BUSINESS Chugai Pharmaceutical to Promote Executive VP Kosaka as President and COO
February 2, 2012
-
BUSINESS Kyowa Kirin Development Chief Hanai Set to Become Company President
February 1, 2012
-
REGULATORY CSIMC General Assembly Establishes Premium for Prescriptions by Generic Name
January 31, 2012
-
REGULATORY JPO Decides Lipitor Crystal Form “Valid”, Sandoz Calls for Appeal
January 30, 2012
-
ORGANIZATION JPWA Board of Directors Approve By-Category Talks to Be Common Understanding
January 27, 2012
-
REGULATORY Rule Review in Similar Drug Re-Pricing Yields 50 Exemptions Based on Competitiveness
January 26, 2012
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…